We focused on the ratios of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) to arachidonic acid (AA) and explored the significance of these ratios relative to clinical characteristics by age in ischemic stroke patients. Methods: We enrolled patients with acute ischemic stroke who underwent radiological investigations and laboratory examinations, including measurement of serum EPA, DHA, and AA levels, and controls. Patients were classified according to age ( 65, 65-74, and ≥ 75 years) and the tertile of EPA/ AA and DHA/AA ratios, and clinical aspects were compared with these factors. 
Introduction
Stroke is a leading cause of death and disability worldwide 1) . Not only elderly patients but also younger adults are affected by ischemic stroke 2, 3) . Ischemic stroke in elderly patients is related to the progression of atherosclerosis and the high prevalence of atrial fibrillation (AF), whereas non-atherosclerotic mechanisms including patent foramen ovale and mitral valve prolapse could contribute to stroke pathogenesis in young stroke patients 4) . However, emerging insights have shown that the contributions of atherosclerotic risk factors (e.g., hypertension, diabetes, and dyslipidemia) as well as lifestyle factors (e.g., smoking, alcohol consumption, and obesity) for ischemic stroke are critical for young patients [3] [4] [5] [6] . For middle-aged Copyright©2018 Japan Atherosclerosis Society This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.
patients, metabolic syndrome increases the prevalence of ischemic stroke 7) . Thus, the risk factors for ischemic stroke are diverse for young, middle-aged, and elderly patients. Currently, no evidence is available regarding specific biomarkers for determining ischemic stroke risk for patients according to age.
Aortic arch calcification upon chest radiography and white matter lesions upon magnetic resonance imaging (MRI) are related to the development of ischemic stroke 8, 9) . We previously showed a close relationship between aortic arch calcification and cerebral white matter lesions for patients with acute ischemic stroke 10) , and the association of age and atherosclerotic vascular risk factors with those pathological lesions has been reported [11] [12] [13] [14] . However, we could not detect any potential biomarkers for such lesions 10) . The n-3 and n-6 polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and arachidonic acid (AA), are poorly synthesized in the human body. Large-scale epidemiological and clinical trials demonstrated that foods enriched with EPA, DHA, and fish oil reduce the incidence of cardiovascular diseases and stroke 15, 16) . In the Japan Lipid Intervention Study, treatment with EPA and low-dose statins significantly reduced coronary artery diseases as well as stroke compared with statin therapy alone 17) . Some authors have suggested that the ratios of serum n-3 to n-6 PUFAs, such as the EPA/AA and DHA/AA ratios, could be useful markers to determine the incidence of major coronary events, peripheral artery diseases, and early neurological deterioration after acute ischemic stroke [18] [19] [20] [21] .
Aim
We focused on the significance of the ratios of EPA/AA and DHA/AA serum levels by age and the association of these ratios with clinical characteristics including aortic arch calcification and cerebral white matter lesions by age for ischemic stroke patients. In the current study, we aimed to explore the hypothesis that the ratios of EPA/AA and DHA/AA may be linked to younger patients with ischemic stroke, in association with lifestyle risk factors, and may serve as putative biomarkers for aortic arch calcification and cerebral white matter lesions.
Methods

Selection of Subjects
This case series was based on the analysis of data acquired from the prospective registry of 478 patients with acute ischemic stroke who were admitted to the Department of Neurology at Juntendo University variate analyses were entered into the multinomial logistic regression analysis. A two-sided p value of 0.05 was considered significant. All data were analyzed using SPSS version 15.0 for Windows software (SPSS, Chicago, IL, USA).
Results
Study Population
During the study period, 73 patients were excluded due to post-surgical stroke onset after cardiac surgery, hospitalization and receiving hospital meals for ≥ 7 days, administration of intravenous hyperalimentation, or taking EPA and DHA agents, and 405 patients were eligible to participate in the study. Thirty-two patients also were excluded because of missing data including MRI and serum PUFA levels. 24) , 42 patients (11%) had small artery occlusion, 54 (14%) had large artery atherosclerosis, 97 (26%) had cardioembolism, 103 (28%) had stroke with determined etiology, 40 (11%) had stroke with undetermined etiology, and 37 (10%) had a transient ischemic attack. For the controls, 105 subjects whose age and gender were matched to the younger stroke patients aged 65 years were enrolled in the study.
Clinical Characteristics and Radiological and Laboratory Findings by Age Group for Stroke Patients
Baseline characteristics and radiological and laboratory findings were compared among 113 patients aged 65 years, 104 patients aged 65 to 74 years, and 156 patients aged ≥ 75 years ( Table 1) . The frequency of male gender was significantly lower for patients aged ≥ 75, and body mass index (BMI) was significantly higher for younger patients aged 65 years (p 0.005 and p 0.001, respectively). Among atherosclerotic risk factors, the frequencies of hypertension, current cigarette smoking, AF, and coronary artery disease were higher for patients aged 65 to 74, 65, ≥ 75, and 65 to 74 years, respectively (p 0.024, p 0.001, p 0.011, and p 0.001, respectively). NIHSS scores on admission were highest for patients aged ≥ 75 years (p 0.006). On chest X radiograph, older patients aged ≥ 75 years had the highest degree of aortic arch calcification (1.7 0.9, p 0.001). On MRI, the degree of PVH and DSWMH and the frequency of intracranial large artery stenosis upon MRA were significantly higher for elderly patients aged ≥ 75 years
Chest Radiograph Study
On chest radiograph, the extent of aortic arch calcification was evaluated and classified into the following four grades according to the method of a previous study: no visible calcification (grade 0); small spots or a single thin area of calcification (grade 1); one or more areas of thick calcification (grade 2); and circumferential calcification (grade 3) 23) .
MRI Protocol
Diffusion-weighted images, T2-weighted images, fluid-attenuation inversion recovery, and MR angiography (MRA) using a 1.5-Tesla MR scanner equipped with single-shot echo-planar imaging (Visart/EX; Toshiba, Tokyo, Japan) were included in the MRI study. Diagnosis of acute brain infarction was based on the finding of focal hyperintensity that was judged not to be due to normal anisotropic diffusion or magnetic susceptibility artifacts on diffusion-weighted images. The number of infarcts on diffusion-weighted imaging was assessed. Periventricular hyperintensity (PVH) and deep and subcortical white matter hyperintensity (DSWMH) were analyzed to determine the degree of cerebral white matter lesions 11) . Severe intracranial artery stenosis upon MRA was defined as >50% or focal signal loss with the presence of signal reduction in the distal artery. Stenoses of bilateral intracranial carotid, anterior cerebral, middle cerebral, and posterior cerebral arteries upon MRA were examined. MRI findings were assessed by two experienced neuroradiologists who were blinded to the patients' status.
Laboratory Findings
Serum fatty acid levels including those of EPA, DHA, and AA were assayed by gas chromatography at an external laboratory (SRL Inc., Tokyo, Japan). We also analyzed serum levels of LDL-C, HDL-C, triglyceride, glucose, and HbA1c. Blood examinations were carried out within 24 hours of admission, or referral to the Department of Neurology for patients who developed ischemic stroke during hospitalization. For control subjects, blood samples were collected after overnight fasting.
Statistical Analysis
Numerical values are reported as means standard deviations. Baseline characteristics, vascular risk factors, chest radiography findings, brain MRI findings, and laboratory data were compared among groups. Data were statistically analyzed using the chisquare test for categorical variables and the MannWhitney and Kruskal-Wallis tests for nonparametric analyses. All variables with a value of p 0.01 on uni-µg/mL, p 0.007).
Comparison of clinical characteristics and laboratory data between younger stroke patients and control subjects aged 65 years Table 1 also shows the comparison of clinical characteristics of younger stroke patients aged 65 years and the control subjects that were age-and gender-matched to the younger stroke patients. AF was (p 0.001, p 0.001, and p 0.011, respectively). Laboratory data showed that the triglyceride level was highest in younger patients (147.6 100.4 mg/dL, p 0.001), whereas HbA1c was highest in middle-aged patients (6.2 1.1%, p 0.003). Regarding the levels of PUFAs, we found no significant differences in EPA level by age group. However, patients aged 65 years had the highest levels of AA (201.2 61.1 µg/mL, p 0.005) and the lowest levels of DHA (140.4 55.1 264 (71) 111 (30) 242 (65) 74 (20) 79 (21) 46 (12) 10 (3) 4.4 5.6 (36) 76 (73) 25 (24) 22 (21) 21 (20) 5 (5) 116 (74) 48 (31) 96 (62) 10 (6) 43 (28) 23 (15) On the other hand, no significant differences in the EPA/AA and DHA/AA ratios were found between brain infarction and transient ischemic attack, or among stroke subtypes.
Independent Factors among Age Groups in Multinomial Logistic Regression Analysis
Age, male gender, BMI, current smoking, coronary artery disease, NIHSS score, aortic arch calcification, PVH, DSWMH, triglyceride level, HbA1c level, EPA/AA ratio, and DHA/AA ratio were selected for multinomial logistic regression analyses. We excluded more common in younger stroke patients (p 0.001). From laboratory data, HDL-C level was significantly higher in the controls (p 0.001), whereas glucose level was higher in the younger stroke patients (p 0.036). Regarding PUFAs, AA and DHA levels were significantly higher in younger stroke patients (both p 0.001), whereas EPA was not different between these groups.
The Ratios of EPA/AA and DHA/AA Serum Levels among Stroke Patients by Age and for Control Subjects Fig. 1 shows the EPA/AA and DHA/AA ratios for stroke patients aged 65, 65-74, and ≥ 75 years and for control subjects aged 65 years. The ratios of EPA/AA and DHA/AA serum levels were significantly Comparison of the ratios of EPA/AA (A) and DHA/AA (B) serum levels among ischemic stroke patients and control subjects. p 0.006; p 0.001 vs. ischemic stroke patients aged 65 years; p 0.001; p 0.009 vs. ischemic stroke patients aged 65 years. data according to the EPA/AA ( Table 3 ) and DHA/ AA (Table 4 ) tertiles of different ages are shown. Among patients aged 65 years, patients in EPA/AA Tertile I were the youngest (51.5 9.5 years, p 0.010) and had the highest frequency of dyslipidemia (71%, p 0.030) ( Table 3) . Among patients aged 65 to 74 years, patients in EPA/AA Tertile II were the youngest (68.9 2.9 years, p 0.040). We found significant differences in the degree of PVH and DSWMH among tertiles in the middle-aged group (1.3 0.8, p 0.042; 1.1 0.8, p 0.025, respectively). Multiple infarctions were most common in Tertile I in the middle-aged group (54%, p 0.008). In the elderly age group, patients in EPA/AA Tertile I had the highest grade of aortic arch calcification upon chest radiograph (2.0 0.9, p 0.012).
Patients were also divided into three DHA/AA tertiles (Tertile I, 0.666; Tertile II, 0.666 to 0.87; Tertile III, 0.87). Table 4 shows that patients in Tertile I were youngest (52.1 9.0, p 0.024) among those aged 65 years. Multiple infarctions were most DSWMH from the covariates, because PVH and DSWMH could cause coincidental or interfering effects. Age was considered a confounding factor and was also excluded from the covariates. In Models 1 and 2, lower ratios of EPA/AA (odds ratio [OR] 0.18, 95% confidence interval [CI] 0.04-0.81, p 0.026) and DHA/AA (OR 0.09, 95% CI 0.02-0.33, p 0.001) were significantly associated with patients aged 65 years compared with those of elderly patients ( Table 2 ). In Models 1 and 2, BMI, current smoking, and triglyceride levels were significantly related to younger patients (p 0.05), whereas aortic arch calcification and PVH were inversely related to younger patients (p 0.001) ( Table 2 explored. Current data showed that the ratios of EPA/ AA and DHA/AA were substantially lower for stroke patients aged 65 years than those for patients aged 65-74 and ≥ 75 years, as well as those for controls. Further, a lower ratio of EPA/AA but not DHA/AA was related to aortic arch calcification for patients aged ≥ 75 years. Cerebral white matter lesions and multiple infarctions were associated with a lower EPA/ AA ratio for patients aged 65-74 years. From the current investigations, our data showed that the ratios of EPA/AA and DHA/AA serum levels for ischemic stroke patients aged 65, 65-74, and ≥ 75 years were 0.35 0.23, 0.43 0.25, and 0.40 0.22, and 0.73 0.27, 0.83 0.27, and 0.83 0.25, respectively, and, for control subjects aged 65 years, the ratios were 0.49 0.25 and 0.82 0.26, respectively, indicating that younger stroke patients aged frequently found in Tertile II of younger stroke patients (49%, p 0.001). For patients aged 65 to 74 years, LDL-C and HDL-C levels were lowest in Tertile I (102.6 32.1, p 0.034; 44.6 11.2, p 0.036, respectively). However, we did not observe significant increases in advanced aortic arch calcification or white matter lesions for patients of any age, which was not consistent with the classification according to EPA/AA tertiles.
Discussion
In the present study, patients' characteristics and radiological and laboratory findings including the ratios of EPA/AA and DHA/AA serum levels were analyzed by age, and age-stratified clinical aspects related to the EPA/AA and DHA/AA ratios were research has suggested that Westernized dietary habits of young Japanese, Whites, and Japanese Americans, as well as of young stroke patients in the current study, may be related to a reduction in the EPA/AA and DHA/AA ratios 22, 25) . Moreover, EPA levels were higher in older subjects than in young subjects in the setting of n-3 PUFA supplementation, indicating that the ability to incorporate dietary EPA into plasma phospholipids is greater in older than in younger subjects 26, 27) . On the other hand, BMI, current smoking, and triglyceride levels were associated with young stroke patients, while those lifestyle risk factors were not different from those of the controls. Although 65 years displayed a substantial reduction in EPA/AA and DHA/AA ratios compared with the ratios of older stroke patients as well as healthy subjects of the same age. A previous study showed that the EPA/AA ratio in healthy Japanese subjects aged 35 years is 0.26 but significantly increases with age and reaches 0.68 by ages of ≥ 65 years 22) . Another study explored the PUFA levels of White, Japanese, and Japanese American men aged 40-49 years, and the estimation of EPA/AA and DHA/AA ratios were about 0.09, 0.39, and 0.12, and 0.27, 0.91, and 0.37, respectively 25) . Because PUFAs are poorly synthesized in the human body and must be obtained through dietary sources, (Cont Table 3 (31) 96 (62) 10 (6) 43 (28) 23 (15) 5 (3) (24) 32 (70) 4 (9) 8 (17) 6 (13) 1 (2) (33) 30 (56) 3 (6) 14 (26) 9 (17) 2 (4) (34) 34 (61) 3 (5) 21 (38) 8 (14) 2 (4) ogy. Pathologically, a variety of mechanisms for ischemic stroke such as thrombosis related to the burden of atherosclerotic plaques, blood stagnation, small artery disorders, and coagulation abnormalities exist. n-3 PUFAs have potent anti-inflammatory effects and inhibitory effects on platelet aggregation, and they enhance nitric oxide-mediated vasodilation [30] [31] [32] . In particular, n-3 PUFAs stabilize atherosclerotic plaques, which may be a fundamental preventive factor for ischemic stroke 33) . Our data did not indicate any significant differences among stroke subtypes. Although n-3 PUFAs have been reported to reduce the incidence of ischemic stroke from large-scale studies 17) , the contribution of PUFAs to stroke mechanisms and subtypes is yet to be elucidated 34, 35) . In the current study, a low EPA/AA ratio was sig-BMI and serum levels of triglycerides may also be affected by diet, our data did not suggest a link between PUFAs and lifestyle risk factors 28, 29) . As stated above, the ratios of EPA/AA and DHA/AA could be related to younger patients, for the first time indicating that the EPA/AA and DHA/AA ratios might be possible additional risk factors for ischemic stroke for younger patients. However, precise dietary data from enrolled subjects, including other lifestylerelated factors (e.g., physical activity and abdominal circumference), were not investigated in the current study, and, thus, further studies are warranted.
According to TOAST criteria, ischemic stroke subtypes include small artery occlusion, large artery atherosclerosis, cardioembolism, stroke with determined etiology, and stroke with undetermined etiol- (20) 32 (65) 22 (45) 3 (6) 1 (2) 79 (76) 37 (36) 76 (73) 25 (24) 22 (21) 21 (20) 5 (5) nificantly associated with aortic arch calcifications upon chest radiograph for elderly stroke patients aged ≥ 75 years and with the degree of cerebral white matter lesions and multiple infarctions for middle-aged patients aged 65-74 years. Aortic arch calcification and cerebral white matter lesions are commonly correlated with age and atherosclerotic risk factors [10] [11] [12] [13] [14] . More importantly, aortic arch calcification and cerebral white matter lesions may share common pathophysiological mechanisms including inflammation, oxidative stress, apoptosis of vascular smooth muscle cells, and endothelial injury [36] [37] [38] [39] [40] . In experimental studies, EPA reduces aneurysm formation as well as vascular calcification in the mouse abdominal aorta via inhibition of matrix metalloproteinase 2 and 9 expression 36, 41) . Moreover, n-3 PUFAs have potent anti-inflammatory effects, and proatherogenic and proinflammatory effects on endothelial cells [30] [31] [32] . Thus, n-3 PUFAs may suppress those pathologic processes and thereby inhibit aortic arch calcification and cerebral white matter lesions. On the other hand, multiple infarctions could indicate the presence of atherosclerotic embolic sources in the carotid artery or aortic arch 42, 43) . n-3 PUFAs also decrease the accumu-(Cont Table 4 lation of inflammatory cytokines such as tumor necrosis factor-, interleukin-6, and matrix metalloproteinase 1/2 in carotid atherosclerotic plaques 33) , and, thus, low EPA levels may lead to the development of embolic stroke owing to atherosclerotic plaques. To date, several studies have documented that cerebral white matter lesions are related to PUFAs for patients with atherosclerotic risk factors and for stroke patients, whereas no clinical studies have explored the association of aortic arch calcification and multiple infarctions with PUFAs 44, 45) . Our data showed that these findings did not correspond to the DHA/AA ratio, which was consistent with previous studies 19, 20) . Thus, a low EPA/AA ratio might be linked to aortic arch calcification for elderly stroke patients as well as to cerebral white matter disease and multiple infarctions for middle-aged stroke patients.
Some potential limitations must be considered when interpreting the results of this study. First, the data from the current study were derived from a single center, and the number of patients in each tertile in the different age groups was quite small. Additionally, we excluded 73 patients owing to post-surgical stroke onset after cardiac surgery, hospitalization and receiving hospital meals for ≥ 7 days, administration of intravenous hyperalimentation, or taking EPA and DHA agents, as well as 32 patients because of missing data including MRI findings and serum PUFA levels, thus raising the issue of the generalizability of the results. Second, the blood examinations were done within 24 hours of admission, or referral to the Department of Neurology for patients who developed ischemic stroke during hospitalization. Therefore, an additional issue is that the EPA/AA and DHA/AA ratios could have been affected by the stroke itself, diet, or infusion therapy after admission. These ratios were analyzed only once after admission. Third, the cross-sectional nature of the present study limits the interpretation of the potential importance of the duration of hypertension, diabetes mellitus, and dyslipidemia, as well as the history of receiving treatments such as statins, anti-thrombotic agents, and angiotensin-converting enzyme inhibitors, before the onset of ischemic stroke. These factors may have affected the patients' characteristics. Accordingly, the current data need to be interpreted with caution.
Conclusions
The ratios of EPA/AA and DHA/AA serum levels could be specifically associated with younger stroke patients, and it is suggested that the EPA/AA and DHA/AA ratios might be possible additional risk factors for ischemic stroke for younger patients. Additionally, the EPA/AA ratio may be related to aortic arch calcification for elderly stroke patients and to cerebral white matter disease and multiple infarctions for middle-aged stroke patients. The current results could be promising but have some limitations and, therefore, should be validated in large-scale clinical trials.
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